Immunotherapy has become a strategy for treatment of Alzheimer's disease, by inducing antibody response to amyloid-ß peptide (AßP) or by passive administration of anti-AßP antibodies. Clearance of amyloid plaques involves interaction of immunoglobulin Fc receptor (FcR)-expressing microglia and antibodyopsonized Aß deposits, stimulating phagocytosis but may promote neuroinflammation. Carbohydrate moiety of Fc of the immunoglobulin G molecule plays a significant role in modulating binding to FcR and its effector functions. Here, we enzymatically removed Fc glycan from monoclonal antibody 196 raised against AßP. Antigen binding ability and in vitro stability of deglycosylated antibody were unaffected by deglycosylation. M oreover, the deglycosylated antibody exhibits low affinity to FcR on microglial BV-2 cells and has limited ability to mediate microglial chemotaxis and antibodydependent cytotoxicity compared to native antibody. These data suggest that deglycosylation of anti-Aß antibodies before in vivo administration might prevent microglial overactivation, thus reducing the risk of neuroinflammatory response during passive immunization.
Wilcock DM, Rojiani A, Rosenthal A, et al.: Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci. 2004; 24: 6144-6151.
2.
Schenk D, Barbour R, Dunn W, et al.: Immunization with amyloidbeta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999; 400 (6740): 173-177.
3.
Wilcock DM, Gordon MN, Ugen KE, et al.: Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol. 2001; 20: 731-736.
4.
Wilcock DM, DiCarlo G, Henderson D, et al.: Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci. 2003; 23: 3745-3751.
5.
Solomon B, Koppel R, Frankel D, et al.: Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci USA. 1997; 94: 4109-4112.
6.
DeMattos RB, Bales KR, Cummins DJ, et al.: Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2001; 98: 8850-8855.
7.
Dodart JC, Bales KR, Gannon KS, et al.: Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 2002; 5: 452-457.
8.
Lemere CA, Spooner ET, LaFrancois J, et al.: Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis. 2003; 14: 10-18.
9.
Bard F, Cannon C, Barbour R, et al.: Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000; 6: 916-919.
10.
Lue LF, Walker DG: Modeling Alzheimer's disease immune therapy mechanisms: Interactions of human postmortem microglia with antibodyopsonized amyloid beta peptide. J Neurosci Res. 2002; 70: 599-610.
11.
Castano A, Lawson LJ, Fearn S, et al.: Activation and proliferation of murine microglia are insensitive to glucocorticoids in Wallerian degeneration. Eur J Neurosci. 1996; 8: 581-588.
12.
Chao CC, Gekker G, Hu S, et al.: Human microglial cell defense against Toxoplasma gondii. The role of cytokines. J Immunol. 1994; 152: 1246-1252.
13.
Boje KM, Arora PK: Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death. Brain Res. 1992; 587: 250-256.
14.
Chao CC, Hu S, Molitor TW, et al.: Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol. 1992; 149: 2736-2741.
15.
Nicoll JA, Wilkinson D, Holmes C, et al.: Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report. Nat Med. 2003; 9(4): 448-452.
16.
Das P, Golde TE: Open peer commentary regarding Abeta immunization and CNS inflammation by Pasinetti et al. Neurobiol Aging. 2002; 23(5): 671-674, discussion 683-684.
17.
Radaev S, Sun PD: Recognition of IgG by Fcgamma receptor. The role of Fc glycosylation and the binding of peptide inhibitors. J Biol Chem. 2001; 276: 16478-16483.
18.
Nose M, Wigzell H: Biological significance of carbohydrate chains on monoclonal antibodies. Proc Natl Acad Sci USA. 1983; 80: 6632-6636.
19.
Jefferis R, Goodall M, Tishchenko V, et al.: Glycosylation of antibody molecules. A small step for structure, a leap for function. Adv Exp Med Biol. 1995; 376: 153-153.
20.
Collin M, Svensson MD, Sjoholm AG, et al.: EndoS and SpeB from Streptococcus pyogenes inhibit immunoglobulin-mediated opsonophagocytosis. Infect Immun. 2002; 70: 6646-6651.
21.
Gordon S: The macrophage. Bioessays. 1995; 17: 977-986.
22.
Bocchini V, Mazzolla R, Barluzzi R, et al.: An immortalized cell line expresses properties of activated microglial cells. J Neurosci Res. 1992; 31: 616-621.
23.
Akiyama H, Arai T, Kondo H, et al.: Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer Dis Assoc Disord. 2000; 14Suppl 1: S47-S53.
24.
Lue LF, Walker DG, Rogers J: Modeling microglial activation in Alzheimer 's disease with human postmortem microglial cultures. Neurobiol Aging. 2001; 22: 945-956.
25.
Glenner GG, Wong CW, Quaranta V, et al.: The amyloid deposits in Alzheimer's disease: Their nature and pathogenesis. Appl Pathol. 1984; 2: 357-369.
26.
Itagaki S, McGeer PL, Akiyama H, et al.: Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol. 1989; 24: 173-182.
27.
Barger SW, Harmon AD: Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein ENature. 1997; 388: 878-881.
28.
Egensperger R, Kosel S, von Eitzen U, et al.: Microglial activation in Alzheimer disease: Association with APOE genotype. Brain Pathol. 1998; 8: 439-447.
29.
Benveniste EN, Nguyen VT, O’Keefe GM: Immunological aspects of microglia: Relevance to Alzheimer's disease. Neurochem Int. 2001; 39: 381-391.
30.
Games D, Bard F, Grajeda H, et al.: Prevention and reduction of AD-type pathology in PDAPP mice immunized with A beta 1-42. Ann N Y Acad Sci. 2000; 920: 274-284.
31.
Fields WS (Ed.): Neurological and Sensory Disorders in the Elderly. New York: Stratton Intercontinental Medical Book, 1975.
32.
Bacskai BJ, Kajdasz ST, McLellan ME, et al.: Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci. 2002; 22: 7873-7878.
33.
Das P, Howard V, Loosbrock N, et al.: Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knockout mice. J Neurosci. 2003; 23: 8532-8538.
